Seelos starts initial dosing in Phase 1 study of its SLS-002 intranasal ketamine depression drug - Proactive Investors USA & Canada

Submitted by Anonymous (not verified) on Wed, 11/20/2019 - 15:24

Seelos starts initial dosing in Phase 1 study of its SLS-002 intranasal ketamine depression drug  Proactive Investors USA & Canada